Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Nucleosides --- Nucleotides --- Nucleosides. --- Nucleotides. --- Nucléosides --- Nucléotides --- Phosphonucleosides --- Nucleic acids --- Nucleoside Analogs --- Analogs, Nucleoside --- Organic Chemistry --- Nucleotide --- Nucleoside --- Nucleoside Analog --- Analog, Nucleoside --- Nucléosides. --- Nucléotides.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cell Nucleus --- Nucleoside Deaminases --- RNA Precursors --- Adenosine Deaminase --- RNA Processing, Post-Transcriptional --- metabolism --- genetics --- metabolism --- genetics

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Adenosine Deaminase --- DNA --- DNA Repair --- Fibroblasts --- Nucleoside Deaminases --- Transcription, Genetic --- genetics --- metabolism --- metabolism --- genetics

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Marine natural products are characterized by high chemical diversity, biochemical specificity, and other molecular properties that make them favorable as lead structures for drug discovery. In this field, one of the main problems is often the reduced natural availability of isolated substances, which can complicate both the structural characterization and possible future developments. For these reasons, the study of bioactive marine metabolites should rely on the development of chemical synthesis and synthetic strategies aimed at the preparation of pure compounds and analogs both for structural confirmation and/or for the large-scale preparation necessary for future applications. Moreover, natural products can be a crucial starting point for the preparation of molecules structurally inspired by the latter, opening the path to new classes of biologically active compounds with pharmacological potential. This book collects original research articles regarding synthetic strategies for secondary marine metabolites and/or analogs that favor applications of these molecules and/or solve structural challenges common in the field of natural substances.

organic synthesis --- meroterpenoids --- thiazinoquinones --- antiproliferative activity --- G0/G1 cell-cycle arrest --- cytostatic --- solid tumor cell lines --- alkylglycerol (AKG) --- ricinoleic acid (RA) --- antimicrobial activity --- structure–activity relationship (SAR) studies --- antibiotics (gentamicin --- tetracycline --- ciprofloxacin and ampicillin) --- marine-inspired --- breast cancer --- bis-indoles --- synthesis --- apoptosis --- carbohydrates --- polysaccharides --- semi-synthesis --- sulfation --- glycosylation --- fucose --- fucosylated chondroitin sulfate --- marine natural product --- largazole --- HDAC inhibitors --- modification --- fluoro olefin --- total synthesis --- natural product --- 7-deazapurine nucleoside --- disaccharide nucleoside --- tubercidin --- aureol --- tetracyclic meroterpenoids --- natural products synthesis --- labdane scaffold --- bioactive diterpenes --- sclareolide --- structure-activity relationships --- TRPV4 channel --- amides/esters --- COVID-19 --- SARS-CoV-2 --- lipophilic iminosugars --- polymer-supported triphenyl phosphine --- cholesterol --- antibacterial iminosugars --- n/a --- structure-activity relationship (SAR) studies

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pharmacogenomics is one of the emerging approaches to precision medicine, tailoring drug selection and dosing to the patient’s genetic features. In recent years, several pharmacogenetic guidelines have been published by international scientific consortia, but the uptake in clinical practice is still poor. Many coordinated international efforts are ongoing in order to overcome the existing barriers to pharmacogenomic implementation. On the other hand, existing validated pharmacogenomic markers can explain only a minor part of the observed clinical variability in the therapeutic outcome. New investigational approaches are warranted, including a study of the pharmacogenomic role of the immune system genetics and of previously neglected rare genetic variants, reported to account for a large part of inter-individual variability in drug metabolism. In this book, we have collected a series of articles covering many aspects of pharmacogenomics. These include clinical implementation of pharmacogenomics in clinical practice, development of tools or infrastructures to support this process, research of new pharmacogenomics markers to increase drug efficacy and safety, and the impact of rare genetic variants in pharmacogenomics.

Medicine --- CYP2C9 --- VKORC1 --- warfarin --- warfarin initiation phase of therapy --- INR --- pharmacogenetics study --- pharmacogenomics --- pharmacogenetics --- genotype --- phenotype --- alleles --- precision medicine --- pharmacotranscriptomics --- high-throughput analysis --- childhood acute lymphoblastic leukemia --- clopidogrel --- acenocoumarol --- CDSS --- implementation --- azathioprine --- inflammatory bowel disease --- glutathione-S transferase --- pharmacokinetics --- nucleoside analogs --- microRNAs --- gene expression --- drug resistance --- AML --- cisplatin --- nephrotoxicity --- kidney injury --- genetic polymorphisms --- pre-emptive --- panel --- breast cancer subtype --- miRNA --- pathway --- crosstalk network --- precision drugs --- ovarian cancer --- platinum resistance --- focal copy number alterations --- whole exome sequencing --- personalized medicine --- human genetics --- pharmacology --- CYP2C9 --- VKORC1 --- warfarin --- warfarin initiation phase of therapy --- INR --- pharmacogenetics study --- pharmacogenomics --- pharmacogenetics --- genotype --- phenotype --- alleles --- precision medicine --- pharmacotranscriptomics --- high-throughput analysis --- childhood acute lymphoblastic leukemia --- clopidogrel --- acenocoumarol --- CDSS --- implementation --- azathioprine --- inflammatory bowel disease --- glutathione-S transferase --- pharmacokinetics --- nucleoside analogs --- microRNAs --- gene expression --- drug resistance --- AML --- cisplatin --- nephrotoxicity --- kidney injury --- genetic polymorphisms --- pre-emptive --- panel --- breast cancer subtype --- miRNA --- pathway --- crosstalk network --- precision drugs --- ovarian cancer --- platinum resistance --- focal copy number alterations --- whole exome sequencing --- personalized medicine --- human genetics --- pharmacology